Results 161 to 170 of about 498,238 (269)
ABSTRACT Non‐severe aplastic anemia (NSAA) is a heterogeneous bone marrow failure syndrome with limited standardized treatment options. Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies.
Lele Zhang +18 more
wiley +1 more source
Loss of antiphospholipid antibody positivity decreases the risk of recurrent thrombosis in thrombotic antiphospholipid syndrome. [PDF]
Gaspar P +13 more
europepmc +1 more source
Why We Do Not Recommend That People With High‐Risk Smoldering Myeloma Receive Treatment
American Journal of Hematology, EarlyView.
Ghulam Rehman Mohyuddin +3 more
wiley +1 more source
ABSTRACT Sickle cell disease (SCD) is a chronic inflammatory state, characterized by increased plasma values of inflammatory and angiogenic proteins. Although red blood cell (RBC) transfusion is known to have immunomodulatory effects in other conditions, its potential effects on the inflammatory state in SCD remain largely unknown.
Lydian A. de Ligt +9 more
wiley +1 more source
Spontaneous Bacterial Peritonitis in Prehepatic Portal Hypertension: A Rare Complication. [PDF]
Mendoza-Rodríguez R +4 more
europepmc +1 more source
Portal vein thrombosis with ruptured oesophageal varices as presenting manifestation of hereditary protein C deficiency. [PDF]
Dominique Valla +4 more
openalex +1 more source
Unusual presentation of colonic angiodysplasia with recurrent ischemia and venous thrombosis. [PDF]
Alanzi A +6 more
europepmc +1 more source
A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo
ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong +5 more
wiley +1 more source

